tetano
Editor, Senior Moderator
Pathogens
. 2022 Jan 27;11(2):171.
doi: 10.3390/pathogens11020171.
Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations
Caiqin Hu[SUP] 1 [/SUP], Dan Li[SUP] 2 [/SUP], Zhanmou Liu[SUP] 3 [/SUP], Li Ren[SUP] 2 [/SUP], Junwei Su[SUP] 1 [/SUP], Meiling Zhu[SUP] 2 [/SUP], Yi Feng[SUP] 2 [/SUP], Zheng Wang[SUP] 2 [/SUP], Qiang Liu[SUP] 4 [/SUP], Biao Zhu[SUP] 1 [/SUP], Yiming Shao[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Assessing the duration of neutralizing antibodies (nAbs) following SARS-CoV-2 infection or vaccination is critical to evaluate the protective immunity and formulate public health strategies. In this study, SARS-CoV-2 Ab ELISA (enzyme-linked immunosorbent assay), chemiluminescent microparticle immunoassay (CMIA), as well as pseudovirus neutralization test (PVNT) were performed in two cohorts, convalescent patients (CP) from coronavirus disease 2019 (COVID-19) and BBIBP-CorV vaccinated population. It was found that nAbs and binding antibodies emerged at 14 days post the 1st dose of vaccination, reached peaks at 28 days after 2nd dose vaccination and then gradually declined over time. CP-6M (convalescent patients up to 6 months) from COVID-19 presented stronger nAbs or binding antibodies responses than vaccinees 90 days or 180 days after 2nd dose vaccination. CMIA or SARS-CoV-2 Ab ELISA correlated well with PVNT with high consistency in the two cohorts. It shown that nAbs and binding antibodies can keep 6 months both in CP and vaccinees. Most importantly, our data show the application of using CMIA and SARS-CoV-2 Ab ELISA as rapid screening tests for nAb titer and could be used as alternative strategies for quickly evaluating SARS-CoV-2 nAbs responses in vaccine research.
Keywords: BBIBP-CorV vaccination; SARS-CoV-2; binding antibodies; convalescent patients (CP); neutralizing antibodies (nAbs).
. 2022 Jan 27;11(2):171.
doi: 10.3390/pathogens11020171.
Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations
Caiqin Hu[SUP] 1 [/SUP], Dan Li[SUP] 2 [/SUP], Zhanmou Liu[SUP] 3 [/SUP], Li Ren[SUP] 2 [/SUP], Junwei Su[SUP] 1 [/SUP], Meiling Zhu[SUP] 2 [/SUP], Yi Feng[SUP] 2 [/SUP], Zheng Wang[SUP] 2 [/SUP], Qiang Liu[SUP] 4 [/SUP], Biao Zhu[SUP] 1 [/SUP], Yiming Shao[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 35215115
- DOI: 10.3390/pathogens11020171
Abstract
Assessing the duration of neutralizing antibodies (nAbs) following SARS-CoV-2 infection or vaccination is critical to evaluate the protective immunity and formulate public health strategies. In this study, SARS-CoV-2 Ab ELISA (enzyme-linked immunosorbent assay), chemiluminescent microparticle immunoassay (CMIA), as well as pseudovirus neutralization test (PVNT) were performed in two cohorts, convalescent patients (CP) from coronavirus disease 2019 (COVID-19) and BBIBP-CorV vaccinated population. It was found that nAbs and binding antibodies emerged at 14 days post the 1st dose of vaccination, reached peaks at 28 days after 2nd dose vaccination and then gradually declined over time. CP-6M (convalescent patients up to 6 months) from COVID-19 presented stronger nAbs or binding antibodies responses than vaccinees 90 days or 180 days after 2nd dose vaccination. CMIA or SARS-CoV-2 Ab ELISA correlated well with PVNT with high consistency in the two cohorts. It shown that nAbs and binding antibodies can keep 6 months both in CP and vaccinees. Most importantly, our data show the application of using CMIA and SARS-CoV-2 Ab ELISA as rapid screening tests for nAb titer and could be used as alternative strategies for quickly evaluating SARS-CoV-2 nAbs responses in vaccine research.
Keywords: BBIBP-CorV vaccination; SARS-CoV-2; binding antibodies; convalescent patients (CP); neutralizing antibodies (nAbs).